News | December 16, 2009

University of Virginia Collaborates to Develop New Cardio Drugs

December 17, 2009 – The University of Virginia (UVa) in Charlottesville and AstraZeneca this week entered into a strategic research collaboration to enhance development of new treatments, primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).

The collaborative preclinical research projects will focus on identifying disease mechanisms and biological targets that have the potential to be starting points for successful and commercially viable treatments of these diseases. The financial terms of the deal were not disclosed.

Atherosclerosis is one of the primary causes of heart diseases, stroke and often death in both men and women in western societies. All evidence suggests that this will increase further as risk factors such as poor diet, increased body weight, and a sedentary lifestyle all increase and the prevalence of obesity and diabetes mellitus reach epidemic proportions globally.

The traditional nonsurgical approach to managing CAD has been through treatment of risk factors such as dyslipidemia, hypertension, diabetes, obesity and others. New and innovative approaches, which act directly on the disease in the vessel wall to slow the progression of, regress, or stabilize the atherosclerotic plaque, could be important, especially when linked to novel biomarkers of vulnerable plaque.

“This is an area of high unmet medical need: atherosclerosis is a primary cause of cardiovascular morbidity and mortality,” said Bjorn Wallmark, vice president of cardiovascular and gastrointestinal research, AstraZeneca. “AstraZeneca is committed to finding innovative solutions. By partnering with the University of Virginia and working together on the complex biology of these diseases it increases the potential of delivering new treatment options.”

“We are very pleased to join AstraZeneca in advancing the science of cardiovascular research,” said Gary Owens, director of UVa’s Robert M. Berne Cardiovascular Research Center and UVa principal investigator of the AstraZeneca-UVa Alliance. “Our partnership has the potential to greatly speed up the development of novel drugs to treat diseases in several targeted areas, taking these projects years ahead in some cases.”

For more information: www.astrazeneca.com

Related Content

Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals | May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals | April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
Overlay Init